Mesenkia Therapeutics AB
559443-7021ActiveDeveloping novel antibodies to treat aggressive brain cancer glioblastoma.
Pre-clinical Biotechnology Companymesenkiatherapeutics.com
Oversikt
- 1–4
- Ansatte
- 200–299t SEK
- Omsetning
- 2023
- Grunnlagt
Beskrivelse
Mesenkia is a pre-clinical biotechnology company focused on developing breakthrough therapies for glioblastoma, an aggressive form of brain cancer. The company specializes in creating next-generation biological drug candidates, specifically single domain antibodies. Their scientific foundation stems...
Tagger
B2BHealthTechPharmaceuticals
Nøkkelord
BiotechDrug Development